BioSpace News Archive

Repare Therapeutics Inc., a leading clinical-stage precision oncology company, announced it has been selected for an oral presentation of clinical data from its ongoing Phase 1/2 TRESR trial of RP-3500, a potent and selective oral small molecule inhibitor of ATR, as well as two additional poster presentations at the upcoming 2022 AACR Annual Meeting held in New Orleans on April 8-13, 2022.

Asana BioSciences, LLC, a clinical stage biopharmaceutical company, today announced that the first patient has been dosed in a Phase 1 trial for ASN004, an antibody drug conjugate (ADC) targeting the 5T4 oncofetal antigen (trophoblast glycoprotein), that is expressed in a wide range of malignant tumors but shows very limited expression in normal tissues.

The global pacemakers market size was valued at USD 3.4 billion in 2020, and is predicted to be worth around USD 6.01 billion by 2030, registering a CAGR of 3.6% during the forecast period 2022 to 2030.

The global pharmacy market size was valued at USD 1,009.5 billion in 2020, and is predicted to be worth around USD 1,522.1 billion by 2030, registering a CAGR of 4.8% during the forecast period 2022 to 2030.

Modern medicine has evolved drastically over the years. From home remedies to targeted medicines, the healthcare sector has witnessed significant breakthroughs.

Zynex, Inc today announced preliminary results for first quarter 2022, affirming guidance for revenue, EBITDA and order growth.

IsoPlexis Corporation (NASDAQ: ISO ), the Superhuman Cell Company, today announced that data generated using its Duomic™ platform demonstrates the ability to connect T Cell Receptor (TCR) diversity to the most functionally potent single cells.

Novocure (NASDAQ: NVCR) today announced 19 presentations on Tumor Treating Fields (TTFields) will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2022, to be held in New Orleans from April 8 to April 13, 2022.

Lyra Therapeutics, Inc. (Nasdaq: LYRA) today announced that it has entered into a securities purchase agreement to sell securities in a private placement that is expected to result in gross proceeds of approximately $100.5 million, before deducting offering expenses.

BeyondSpring Inc., a global biopharmaceutical company focused on the development of innovative cancer therapies, announced that it will report its financial results for the quarter and year ended December 31, 2021 before market open on Thursday, April 14, 2022.